Modulation of systemic interleukin-6 induction by central interleukin-1

Area of Science:

• Neuroimmunology
• Endocrinology
• Cytokine signaling

Background:

• Interleukin-1 (IL-1) plays a crucial role in mediating inflammatory and immune responses.
• The brain's involvement in regulating systemic cytokine levels, such as IL-6, during the acute phase response is not fully understood.
• Understanding the central pathways activated by IL-1 is essential for comprehending neuroinflammatory processes.

Purpose of the Study:

• To investigate the role of central interleukin-1 (IL-1) in inducing serum IL-6 production.
• To identify the specific brain receptors and signaling pathways involved in IL-1-mediated IL-6 induction.
• To explore the influence of corticosteroids and opioid systems on this neuro-immune interaction.

Main Methods:

• Rats received central (intracerebroventricular) or systemic administration of IL-1 alpha and beta.
• Interleukin-1 receptor antagonist (IL-1Ra), CRF antiserum, CRF antagonist, dexamethasone, and naloxone were used to block specific pathways.
• Serum IL-6 levels were measured, and IL-6 concentrations in specific brain regions were analyzed.

Main Results:

• Central IL-1 administration induced a greater increase in serum IL-6 compared to systemic injection.
• This effect was blocked by IL-1 receptor antagonist and dexamethasone, but not by CRF antagonists.
• Naloxone, but not its peripheral-acting quaternary salt, antagonized IL-1-induced IL-6, suggesting central opiate involvement. Brain IL-6 levels remained low.

Conclusions:

• Central IL-1 stimulates serum IL-6 production through brain IL-1 receptors, indicating the brain's significant role in the acute phase response.
• Corticosteroids and central opioid pathways are key modulators of this IL-1-driven systemic IL-6 response.
• The brain primarily influences systemic IL-6 via non-brain pathways, rather than direct central IL-6 synthesis.